IGN523 / Igenica Biotherapeutics - LARVOL DELTA

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes (ASH 2017) - P2,P3; "...AML301 was a phase 3 (N=457), multicenter, open-label study that evaluated the efficacy and safety of tipifarnib compared with best supportive care (BSC), including hydroxyurea, as first-line therapy in elderly patients with newly diagnosed, de novo, or secondary AML...CXCL12 expression and BM homing constitute potential biomarkers of the activity of tipifarnib in AML and MDS supporting the hypothesis that the CXCL12 pathway is a potential target of FT inhibitors."

Biomarker • Clinical • Acute Myelogenous Leukemia • Biosimilar • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma

[VIRTUAL] Combining New Agents with „3+7“ Chemotherapy in Fit Patients (ICLLM 2021) - P1b, P3 | "Inthe randomized, placebo-controlled phase III CALGB 10603/RATIFY study which evaluated midostaurin in patients aged18 to 59 years with newly diagnosed FLT3-mutated AML incombination with intensive induction and consolidation therapyfollowed by a one-year oral maintenance therapy, midostaurinsignificantly improved overall survival (OS) and event-freesurvival (EFS).4 Gilteritinib, quizartinib and crenolanib arenext-generation FLT3-inhibitors with a much higher selectivityfor FLT3...Ongoing clinical trialsinclude trials using intensive chemotherapy plus midostaurinversus gilteritinib (NCT04027309), using FLT3-inhibitors formaintenance after allogeneic hematopoietic cell transplantation(HCT) (NCT02997202), or using the combination of gilteritinibwith other novel agents (e.g. venetoclax; NCT03625505).IDH1 and IDH2 mutations are found in approximately 15-25%of patients with newly diagnosed AML; the incidence of themutations increases with older age.1 Ivosidenib and..."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • FLT3 • IDH1 • IDH2

Post-remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favorable and Intermediate-Risk AML. (PubMed, Hematol Oncol) - "Herein we report on the long-term outcome of consecutive unselected AML patients treated with repeated courses of HDAC, with the addition of idarubicin, followed by autologous peripheral-blood stem-cell (PBSC) support, in order to limit toxicity, according to NILG AML-01/00 study (EUDRACT number 00400673). In conclusion, consolidation including repeated courses of HDAC and idarubicin, with limited PBSC support, proved feasible and very effective in non-high risk patients. The incorporation of novel agents in its backbone may be tested to further improve patient's prognosis."

Clinical • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD34 • FLT3

Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment. (PubMed, Leuk Lymphoma) - "PDGFRB expression was upregulated in MMSCs from patients in relapse versus those in remission. The AML 01.10 protocol downregulates the expression of genes related to proliferation, differentiation and niche formation."

Clinical • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Immunology • Leukemia • Oncology

Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group. (PubMed, Pediatr Blood Cancer) - "We report relatively stable rates of ED and TRM in CR1 in the latest completed DCOG protocols for newly diagnosed AML patients. The most important causes of TRM were SCT- or infection-related, warranting further evaluation and awareness."

Clinical • Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics

JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population. (PubMed, Asian Pac J Cancer Prev) - "From the above findings it is evident that the JAK2 V617F mutation is widespread not only in MPD's but also in hematological malignancies, which might as well lead to the new classification of MPD'S. Our data also suggest that different genetic events may lead to JAK-STAT pathway activation in different malignancies."

Clinical • Journal

Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. (PubMed, Pediatr Blood Cancer) - "G-CSF as supportive care was used in a third of patients, and use decreased with time. Our results indicate that the use of G-CSF may be associated with an increased risk of relapse."

Journal

Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. (PubMed, Pediatr Blood Cancer) - "DB AML-01 response-guided therapy results in a favorable OS, particularly for children with CBF leukemia, children younger than 10 years or with initial WBC counts below 100 × 10 /L. Outcome of patients with FLT3-ITD/NPM1-WT remains poor and warrants alternative treatment strategies."

Clinical • Journal

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. (PubMed, Leukemia) - "Multivariable analysis showed a 49% reduction in risk of death for pAML patients treated according to the latest DB-AML 01 protocol (p = 0.03). The continuing decrease of mortality (AAPC -2.8% per year (95% CI -4.1 to -1.5)) supports the conclusion of true progress against pAML in the Netherlands."

Clinical • Journal

Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. (PubMed, Pediatr Blood Cancer) - "Longer neutrophil recovery time after the first induction course was associated with grade 3-4 infections and relapse. If confirmed, this knowledge could be incorporated into risk stratification strategies in pediatric AML."

Clinical • Journal